Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1072 - Phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): phase Ib results


24 Nov 2018


Poster display - Cocktail


Tumour Site

Colon and Rectal Cancer


Yoshinori Kagawa


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


Y. Kagawa1, H. Satake2, T. Kato3, K. Oba4, H. Yasui5, M. Nakamura6, T. Watanabe7, K. Hirata8, K. Muro9, Y. Komatsu10, T. Yoshino11, K. Yamazaki12, H. Mishima13, M. Kotaka14, A. Tsuji15, Y. Kakeji16, E. Oki17, N. Nagata18, S. Junichi19

Author affiliations

  • 1 Surgery, Kansai Rosai Hospital, 6608511 - Amagasaki/JP
  • 2 Cancer Treatment Center, Kansai Medical University Hospital, Hirakata/JP
  • 3 Surgery, National Hospital Organization, Osaka National Hospital, Osaka/JP
  • 4 Department of Biostatistics, The University of Tokyo, Tokyo/JP
  • 5 Department Of medical Oncology, Kobe City Medical Center General Hospital, Kobe/JP
  • 6 Aizawa Comprehensive Cancer Center, Aizawa Hospital, 390-8510 - Matsumoto City/JP
  • 7 Department of Surgery, Japanese Red Cross Society Himeji Hospital, Himeji/JP
  • 8 Department of SurgeryⅠ, University of Occupational and Environmental Health, Kitakyusyu/JP
  • 9 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 10 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 11 National Cancer Center Hospital East, National Cancer Center Hospital, Kashiwa/JP
  • 12 Department Of Gi Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 13 Department Of Surgery, Aichi Medical University, 480-1195 - Nagakute/JP
  • 14 Surgery, Sano Hospital-Gastrointestinal Cancer Centre, 655-0031 - Kobe/JP
  • 15 Department Of Clinical Oncology, Kagawa University Faculty of Medicine/Graduate School of Medicine, 761-0793 - Kagawa/JP
  • 16 Division Of Gastrointestibal Surgery, Department of Surgery, KobeUniversity Graduate School of Medicine, Kobe/JP
  • 17 Department Of Surgery, Kyushu University Hospital, 812-8582 - Fukuoka/JP
  • 18 Department Of Surgery, Kitakyushu General Hospital, 803-0814 - Kitakyushu/JP
  • 19 Tokai Central Hospital, Tokai Central Hospital, 504-8601 - Kakamigahara/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1072


In patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC), TAS-102 -a combination of trifluridine and tipiracil- plus bevacizumab (bev) combination therapy has shown a promising activity with manageable safety. In previously reported this combination therapy, TAS-102 have been given every 4 weeks (35mg/m2 given orally twice daily on day 1-5 and 8-12 in a 28-day cycle) and bev have been administered every 2 weeks. The aim of this study was to assess the activity and safety of biweekly TAS-102 (given orally twice daily on day 1-5 every 2 weeks) with bev combination for pts with mCRC.


Inclusion criteria were ≥ 20 years; histologically confirmed unresectable metastatic colorectal adenocarcinoma; refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF, and anti-EGFR therapy (for tumors with wild-type RAS); ECOG performance status 0 or 1; evaluable lesion according to the RECIST version 1.1. Using a dose de-escalation design in phase Ib part and we determined the recommended phase II dose (RP2D).


From October 2017 to January 2018, totally 46 pts were enrolled, and six were enrolled in phase Ib part. The patient characteristics of phase Ib part were as follows: median age, 74 (range, 68-82); male, 50%; ECOG PS 0/ 1, 3/ 3 (50/ 50%); right-sided primary/ left-, 2/ 4 (33/ 67%); median prior chemotherapy regimen, 3 (range, 2-4). Of the six pts, grade 3 or higher relevant toxicities during the DLT evaluation period were anemia (n = 1) and anorexia (n = 1). Common grade 3 or higher relevant toxicities through the treatment period were anemia (n = 2), anorexia (n = 2), nausea (n = 2), leucopenia (n = 1) and proteinuria (n = 1). No DLT and no treatment related death was observed. Best overall response was were stable disease in 4 pts (67%), and progressive disease in 2 pts (33%).


Biweekly TAS-102 with bev combination for pts with mCRC showed a promising antitumor activity with acceptable toxicity. The RP2D was determined to as biweekly TAS-102 (35mg/m2 given orally twice daily on day 1-5 every 2 weeks) with bev (5mg/kg, every 2 weeks).

Editorial acknowledgement

Clinical trial identification


Legal entity responsible for the study





T. Kato: Chugai Pharmaceutical CO., Ltd, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Bayer Yakuhin, Ltd., Sanofi S.A., Yakult Honsha Company, Limited. K. Oba: Consultant fee: Takeda Pharmaceutical Co. Inc., Ono Pharma Icn., Asahi-Kasei Pharma Inc.; Honoraria: Eisai Co.Inc., Chugai Pharmaceutical Co. Inc., Daiichi-Sankyo Co. Inc. K. Muro: Grants: Ono, MSD, Daiichi Sankyo, Kyowa Hakko Kirin, Shionogi, Pfizer, Gilead Sciences, Merck Serono; Personal fees: Chugai, Taiho, Takeda, Bayer, Eli Lilly, personal fees from outside the submitted work. Y. Komatsu, A. Tsuji, Y. Kakeji: Honoraria: Taiho, Chugai, Takeda, Eli Lilly. T. Yoshino: Grants/research suppots: MSD, Sanofi, Sumitomo Dainippon, Chugai, GlaxoSmithKline, Nippon Boehringer Ingelheim; Honoraria or consultation fees: Sanofi, Chugai, Eli Lilly, Merck Serono. K. Yamazaki: Honoraria: Chugai, Taiho. M. Kotaka: Honoraria: Chugai, Yakult, Takeda, Eli Lilly. E. Oki: Honoraria: Taiho, Chugai, Takeda, Merck Serono, Eli Lilly. S. Junichi: Consultant fee: Takeda. Honoraria: Chugai, Tsumura, Nihon Kayaku. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.